FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / BMC Vet Res / The efficacy and safety of velagliflozin over 16 weeks as ...
BMC veterinary research2019; 15(1); 65; doi: 10.1186/s12917-019-1811-2

The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies.

Abstract: A previous six-week (wk) study demonstrated the potential of the sodium-glucose linked transport inhibitor velagliflozin as a novel treatment for equine insulin dysregulation. The present study examined the safety and efficacy of velagliflozin over 16 wk. of treatment, and over 4 wk. of withdrawal. Twenty-four insulin dysregulated ponies were selected, based on their hyper-responsiveness to a diet challenge meal containing 3.8 g non-structural carbohydrates (NSC)/kg bodyweight (BW). Ponies with serum insulin > 90 μIU/mL either 2 or 4 h after feeding were enrolled, and randomly allocated to receive either velagliflozin (0.3 mg/kg BW orally once daily, n = 12), or a placebo (n = 10-12) for 16 wk. The subjects were fed 7.5 g NSC/kg BW/day to maintain a fat body condition. Safety was assessed through daily monitoring, veterinary examination, and the measurement of fasting blood glucose, biochemistry and haematology. Efficacy at reducing post-prandial hyperinsulinemia was assessed using a diet challenge every 8 wk. during treatment and 4 wk. after withdrawal. Results: Velagliflozin was well accepted by all subjects and caused no adverse effects or hypoglycaemia. Post-prandial serum insulin (insulin Cmax) did not change significantly in the control animals over the entire study period (P = 0.101). In contrast, insulin Cmax (mean ± SE) concentrations fell over time in the velagliflozin-treated group from 205 ± 25 μIU/mL in wk. 0, to 119 ± 19 μIU/mL (P = 0.015) and 117 ± 15 μIU/ml (P = 0.029) after 8 and 16 wk. of treatment, respectively. Although the insulin Cmax in this group was not significantly lower than in controls at wk-8 (P = 0.061), it was lower at wk-16 (P = 0.003), and all 12 treated ponies were below the previously-determined risk threshold for laminitis at this time. After 4 wk. withdrawal, the insulin Cmax returned to 199 ± 36 μIU/mL in the treated group, with no rebound effect. Conclusions: Velagliflozin appears to be a promising and safe treatment for equine insulin dysregulation, bringing post-prandial insulin concentrations below the laminitis risk threshold, albeit without normalising them.
Get Full Text
Publication Date: 2019-02-26 PubMed ID: 30808423PubMed Central: PMC6390376DOI: 10.1186/s12917-019-1811-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Veterinary
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research presents a 16-week study investigating the safety and efficacy of velagliflozin as a treatment for insulin dysregulation in ponies. The results suggest that velagliflozin may be a safe and promising option, with the capacity to reduce insulin concentrations below the laminitis risk level.

Research Study Overview

  • The study seeks to explore the effectiveness of a sodium-glucose linked transport inhibitor known as velagliflozin as a treatment for equine insulin dysregulation over a period of 16 weeks, including 4 weeks of withdrawal.
  • 24 ponies exhibiting insulin dysregulation, defined by a heightened response to a diet challenge meal loaded with 3.8g non-structural carbohydrates (NSCs) per kilogram of body weight, were chosen for the study.

Research Methodology

  • Selection of ponies was based on serum insulin levels greater than 90μIU/mL either 2 or 4 hours after feeding.
  • Ponies were then randomly divided into two groups with one group receiving velagliflozin (0.3 mg/kg BW distributed orally once daily) and the other group given a placebo for a span of 16 weeks.
  • All ponies were fed 7.5g NSC/kg BW/day to maintain a fat body condition.
  • The study evaluated the safety of the drug through daily monitoring, veterinary checks, and measurements of fasting blood glucose, biochemistry, and haematology.
  • Velagliflozin’s effectiveness in decreasing post-prandial hyperinsulinemia was measured through a dietary challenge every 8 weeks during treatment and 4 weeks after withdrawal.

Results of the Study

  • The results demonstrated that all subjects adjusted well to velagliflozin with no hypoglycaemia or negative side effects being reported.
  • Post-prandial serum insulin in the control group remained consistent throughout the research period (P=0.101).
  • In contrast, the velagliflozin-treated group showed a decrease in insulin concentrations from 205 ± 25 μIU/mL in week 0, to 119 ± 19 μIU/mL (P=0.015) and 117 ± 15 μIU/ml (P=0.029) after 8 weeks and 16 weeks of treatment, respectively.
  • Though not significantly lower than the control group’s measurements at week-8 (P=0.061), the levels were lower at week-16 (P=0.003), with all velagliflozin-treated ponies dropping below the pre-determined laminitis risk threshold.
  • After 4 weeks of withdrawal, the velagliflozin-treated group showed an insulin measurement of 199 ± 36 μIU/mL with no rebound effect.

Conclusion

  • The research concludes that velagliflozin is a promising and safe treatment for equine insulin dysregulation.
  • While the treatment doesn’t normalize insulin levels, it does reduce insulin concentrations below the danger zone for laminitis.

Cite This Article

APA
Meier A, de Laat M, Reiche D, Fitzgerald D, Sillence M. (2019). The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies. BMC Vet Res, 15(1), 65. https://doi.org/10.1186/s12917-019-1811-2

Publication

BMC veterinary research
ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 15
Issue: 1
Pages: 65

Researcher Affiliations

Meier, A
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology (QUT), Brisbane, Queensland, 4000, Australia.
de Laat, M
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology (QUT), Brisbane, Queensland, 4000, Australia.
Reiche, D
  • Boehringer Ingelheim Vetmedica, 55218, Ingelheim am Rhein, Germany.
Fitzgerald, D
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology (QUT), Brisbane, Queensland, 4000, Australia.
Sillence, M
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology (QUT), Brisbane, Queensland, 4000, Australia. martin.sillence@qut.edu.au.

MeSH Terms

  • Animals
  • Horse Diseases / blood
  • Horse Diseases / drug therapy
  • Horses
  • Hyperinsulinism / blood
  • Hyperinsulinism / drug therapy
  • Hyperinsulinism / veterinary
  • Hypoglycemic Agents / therapeutic use
  • Insulin / blood
  • Nitriles / therapeutic use
  • Random Allocation
  • Treatment Outcome

Grant Funding

  • na / Boehringer Ingelheim

Conflict of Interest Statement

ETHICS APPROVAL: This study was approved by the Animal Care and Ethics Committees of Queensland University of Technology (1500000204) and The University of Queensland (QUT/SVS/470/14). All procedures were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes (NHMRC, 8th edition, 2013). All animals used in the study were owned by Queensland University of Technology and were used with the consent of the University. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: DR is an employee of the company that funded this research: Boehringer-Ingelheim. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

This article includes 46 references
  1. Frank N, Tadros E. Insulin dysregulation.. Equine Vet J 2014;46(1):103–112.
    pubmed: 24033478
  2. Asplin K, Sillence M, Pollitt C, McGowan C. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies.. Vet J 2007;174(3):530–535.
    pubmed: 17719811
  3. de Laat M, McGowan C, Sillence M, Pollitt C. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses.. Equine Vet J 2010;42(2):129–135.
    pubmed: 20156248
  4. Meier A, de Laat M, Reiche D, Pollitt C, Walsh D, McGree J, Sillence M. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.. Domest Anim Endocrinol 2018;63:1–9.
    pubmed: 29172109
  5. Menzies-Gow N, Harris P, Elliott J. Prospective cohort study evaluating risk factors for the development of pasture-associated laminitis in the United Kingdom.. Equine Vet J 2016;49(3):300–306.
    pubmed: 27363591
  6. Carter R, Treiber K, Geor R, Douglass L, Harris P. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies.. Equine Vet J 2009;41(2):171–178.
    pubmed: 19418747
  7. Treiber K, Kronfeld D, Hess T, Byrd B, Splan R, Staniar W. Evaluation of genetic and metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies.. J Am Vet Med Assoc 2006;228(10):1538–1545.
    pubmed: 16677122
  8. de Laat M, McGree J, Sillence M. Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation.. Am J Physiol Endocrinol Metab 2016;310(1):E61–E72.
    pubmed: 26530154
  9. Harris P, Bailey S, Elliott J, Longland A. Countermeasures for pasture-associated laminitis in ponies and horses.. J Nutr 2006;136(7):2114S–2121S.
    pubmed: 16772514
  10. Menzies-Gow N. Endocrinopathic laminitis: reducing the risk through diet and exercise.. Vet Clin North Am: Equine Pract 2010;26(2):371–378.
    pubmed: 20699181
  11. Freestone J, Beadle R, Shoemaker K, Bessin R, Wolfsheimer K, Church C. Improved insulin sensitivity in hyperinsulinaemic ponies through physical conditioning and controlled feed intake.. Equine Vet J 1992;24:187–190.
    pubmed: 1606931
  12. Powell D, Reedy S, Sessions D, Fitzgerald B. Effect of short-term exercise training on insulin sensitivity in obese and lean mares.. Equine Vet J 2010;34:81–84.
    pubmed: 12405664
  13. de Laat M, Hampson B, Sillence M, Pollitt C. Sustained, low-intensity exercise achieved by a dynamic feeding system decreases body fat in ponies.. J Vet Intern Med 2016;30(5):1732–1738.
    pmc: PMC5032883pubmed: 27639952
  14. Carter R, McCutcheon L, Valle E, Meilahn E, Geor R. Effects of exercise training on adiposity, insulin sensitivity, and plasma hormone and lipid concentrations in overweight or obese, insulin-resistant horses.. J Am Vet Med Assoc 2010;236(5):566.
    pubmed: 20187833
  15. Durham A, Frank N, McGowan C, Menzies-Gow N, Roelfsema E, Vervuert I. ECVIM consensus statement on equine metabolic syndrome.. 2018;1-66.
    pmc: PMC6430910pubmed: 30724412
  16. Fitzgerald D, de Laat M, Harris P, Bailey S. Effect on plasma insulin of a peptide inhibitor of the incretin hormone, GLP-1, in ponies fed a meal containing micronized maize.. Proceedings of the Australasian Equine Science Symposium 2018 June 6-8; Australia p 19.
  17. Kheder M, Bailey S, Dudley K, Sillence M, de Laat M. Equine glucagon-like peptide-1 receptor physiology.. PeerJ 2018;6:1–15.
    pmc: PMC5793710pubmed: 29404215
  18. Kheder M, Sillence M, Bryant L, de Laat M. The equine glucose-dependent insulinotropic polypeptide receptor: a potential therapeutic target for insulin dysregulation.. J Anim Sci 2017;95(6):2509–2516.
    pubmed: 28727072
  19. Chao E. SGLT-2 inhibitors: a new mechanism for glycemic control.. Clin Diabetes 2014;32:4–11.
    pmc: PMC4521423pubmed: 26246672
  20. Meier A, de Laat M, Pollitt C, Walsh D, Sillence M. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.. PLoS One 2018;13(9):e0203655.
    pmc: PMC6136744pubmed: 30212530
  21. Dunbar L, Mielnicki K, Dembek K, Toribio R, Burns T. Evaluation of four diagnostic tests for insulin dysregulation in adult light-breed horses.. J Vet Intern Med 2016;30(3):885–891.
    pmc: PMC4913564pubmed: 27013065
  22. Secombe C, Tan R, Perara D, Byrne D, Watts S, Wearn J. The effect of geographic location on circannual adrenocorticotropic hormone plasma concentrations in horses in Australia.. J Vet Intern Med 2017;31(5):1533–1540.
    pmc: PMC5598888pubmed: 28661009
  23. Henneke D, Potter G, Kreider J, Yeates B. Relationship between condition score, physical measurements and body fat percentage in mares.. Equine Vet J 1983;15:371–372.
    pubmed: 6641685
  24. Carter R, Geor R, Burton Staniar W, Cubitt T, Harris P. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies.. Equine Vet J 2009;179:204–210.
    pubmed: 18440844
  25. . Serum Biochemical Reference Ranges – Appendixes- Veterinary Manual.. .
  26. Wilding J. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.. Metabolism 2014;63:1228–1237.
    pubmed: 25104103
  27. Hoenig M, Clark M, Schaeffer DJ, Reiche D. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.. Feline J Vet Pharmacol Ther 2018;41(2):266–273.
    pubmed: 29139146
  28. Eiler H, Frank N, Andrews F, Oliver J, Fecteau K. Physiologic assessment of blood glucose homeostasis via combined intravenous glucose and insulin testing in horses.. Am J Vet Res 2005;66(9):1598–1604.
    pubmed: 16261835
  29. Banse H, McCann J, Yang F, Wagg C, McFarlane D. Comparison of two methods for measurement of equine insulin.. J Vet Diag Invest 2014;26(4):527–530.
    pubmed: 24928598
  30. Warnken T, Huber K, Feige K. Comparison of three different methods for the quantification of equine insulin.. BMC Vet Res 2016;12:196.
    pmc: PMC5016943pubmed: 27613127
  31. Frank N, Geor R, Bailey S, Durham A, Johnson P. Equine metabolic syndrome.. J Vet Intern Med 2010;24(3):467–475.
    pubmed: 20384947
  32. McGowan C, Dugdale A, Pinchbeck G, Argo C. Dietary restriction in combination with a nutraceutical supplement for the management of equine metabolic syndrome in horses.. Vet J 2013;196(2):153–159.
    pubmed: 23141962
  33. Morgan R, Keen J, McGowan C. Treatment of equine metabolic syndrome: a clinical case series.. Equine Vet J 2015;48(4):422–426.
    pubmed: 25808563
  34. Chen L, Leung P. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.. Diabetes Obes Metab 2013;15:392–402.
    pubmed: 23331516
  35. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde A, Sjöström C. Dapagliflozin maintains glycemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.. Diabetes Obes Metab 2013;16(2):159–169.
    pubmed: 23906445
  36. Kalra S. Sodium glucose co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology.. Diabetes Ther 2014;5(2):355–366.
    pmc: PMC4269649pubmed: 25424969
  37. . ACTH, Insulin and Leptin - ACINLP.. .
  38. Kearns C, McKeever K, Roegner V, Brady S, Malinowski K. Adiponectin and leptin are related to fat mass in horses.. Vet J 2016;172(3):460–465.
    pubmed: 15996495
  39. Van Weyenberg S, Hesta M, Buyse J, Janssens G. The effect of weight loss by energy restriction on metabolic profile and glucose tolerance in ponies.. J Anim Physiol Anim Nutr 2008;92(5):538–545.
    pubmed: 19012597
  40. McManus C, Fitzgerald B. Effects of a single day of feed restriction on changes in serum leptin, gonadotropins, prolactin, and metabolites in aged and young mares.. Domest Anim Endocrinol 2000;19(1):1–13.
    pubmed: 10962194
  41. Fadini G, Bonora B, Zatti G, Vitturi N, Iori E, Marescotti M, Albiero MAvogaro A. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.. Cardiovasc Diabetol 2017;16:42.
    pmc: PMC5379610pubmed: 28376855
  42. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki ELi Q. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.. Eur J Pharmacol 2014;727:66–74.
    pubmed: 24486393
  43. Napolitano A, Miller S, Murgatroyd P, Hussey E, Dobbins R, Bullmore ENunez D. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.. J Clin Transl Endocrinol 2013;1(1):e3–e8.
    pmc: PMC5685025pubmed: 29235586
  44. Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.. Diabetes Obes Metab 2018;20(6):1361–1366.
    pubmed: 29359851
  45. Bertin F, de Laat M. The diagnosis of equine insulin dysregulation.. Equine Vet J 2017;49(5):570–576.
    pubmed: 28543410
  46. Patterson-Kane J, Karikoski N, McGowan C. Paradigm shifts in understanding equine laminitis.. Vet J 2018;231:33–40.
    pubmed: 29429485
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.